Blood DNA methylation as a potential biomarker of dementia

A systematic review

Peter D. Fransquet, Paul Lacaze, Richard Saffery, John McNeil, Robyn Woods, Joanne Ryan

Research output: Contribution to journalArticleResearchpeer-review

8 Citations (Scopus)

Abstract

Dementia is a major public health issue with rising prevalence rates, but many individuals remain undiagnosed. Accurate and timely diagnosis is key for the optimal targeting of interventions. A noninvasive, easily measurable peripheral biomarker would have greatest utility in population-wide diagnostic screening. Epigenetics, including DNA methylation, is implicated in dementia; however, it is unclear whether epigenetic changes can be detected in peripheral tissue. This study aimed to systematically review the evidence for an association between dementia and peripheral DNA methylation. Forty-eight studies that measured DNA methylation in peripheral blood were identified, and 67% reported significant associations with dementia. However, most studies were underpowered and limited by their case-control design. We emphasize the need for future longitudinal studies on large well-characterized populations, measuring epigenetic patterns in asymptomatic individuals. A biomarker detectable in the preclinical stages of the disease would have the greatest utility in future intervention and treatment trials.

Original languageEnglish
Pages (from-to)81-103
Number of pages18
JournalAlzheimer's and Dementia
Volume14
Issue number1
DOIs
Publication statusPublished - Jan 2018

Keywords

  • Alzheimer's disease
  • Biomarker
  • Blood
  • Dementia
  • DNA methylation
  • Epigenetics
  • Peripheral

Cite this

@article{b1e77caa558d42ecae9fa206031fd478,
title = "Blood DNA methylation as a potential biomarker of dementia: A systematic review",
abstract = "Dementia is a major public health issue with rising prevalence rates, but many individuals remain undiagnosed. Accurate and timely diagnosis is key for the optimal targeting of interventions. A noninvasive, easily measurable peripheral biomarker would have greatest utility in population-wide diagnostic screening. Epigenetics, including DNA methylation, is implicated in dementia; however, it is unclear whether epigenetic changes can be detected in peripheral tissue. This study aimed to systematically review the evidence for an association between dementia and peripheral DNA methylation. Forty-eight studies that measured DNA methylation in peripheral blood were identified, and 67{\%} reported significant associations with dementia. However, most studies were underpowered and limited by their case-control design. We emphasize the need for future longitudinal studies on large well-characterized populations, measuring epigenetic patterns in asymptomatic individuals. A biomarker detectable in the preclinical stages of the disease would have the greatest utility in future intervention and treatment trials.",
keywords = "Alzheimer's disease, Biomarker, Blood, Dementia, DNA methylation, Epigenetics, Peripheral",
author = "Fransquet, {Peter D.} and Paul Lacaze and Richard Saffery and John McNeil and Robyn Woods and Joanne Ryan",
year = "2018",
month = "1",
doi = "10.1016/j.jalz.2017.10.002",
language = "English",
volume = "14",
pages = "81--103",
journal = "Alzheimer's and Dementia",
issn = "1552-5260",
publisher = "Elsevier",
number = "1",

}

Blood DNA methylation as a potential biomarker of dementia : A systematic review. / Fransquet, Peter D.; Lacaze, Paul; Saffery, Richard; McNeil, John; Woods, Robyn; Ryan, Joanne.

In: Alzheimer's and Dementia, Vol. 14, No. 1, 01.2018, p. 81-103.

Research output: Contribution to journalArticleResearchpeer-review

TY - JOUR

T1 - Blood DNA methylation as a potential biomarker of dementia

T2 - A systematic review

AU - Fransquet, Peter D.

AU - Lacaze, Paul

AU - Saffery, Richard

AU - McNeil, John

AU - Woods, Robyn

AU - Ryan, Joanne

PY - 2018/1

Y1 - 2018/1

N2 - Dementia is a major public health issue with rising prevalence rates, but many individuals remain undiagnosed. Accurate and timely diagnosis is key for the optimal targeting of interventions. A noninvasive, easily measurable peripheral biomarker would have greatest utility in population-wide diagnostic screening. Epigenetics, including DNA methylation, is implicated in dementia; however, it is unclear whether epigenetic changes can be detected in peripheral tissue. This study aimed to systematically review the evidence for an association between dementia and peripheral DNA methylation. Forty-eight studies that measured DNA methylation in peripheral blood were identified, and 67% reported significant associations with dementia. However, most studies were underpowered and limited by their case-control design. We emphasize the need for future longitudinal studies on large well-characterized populations, measuring epigenetic patterns in asymptomatic individuals. A biomarker detectable in the preclinical stages of the disease would have the greatest utility in future intervention and treatment trials.

AB - Dementia is a major public health issue with rising prevalence rates, but many individuals remain undiagnosed. Accurate and timely diagnosis is key for the optimal targeting of interventions. A noninvasive, easily measurable peripheral biomarker would have greatest utility in population-wide diagnostic screening. Epigenetics, including DNA methylation, is implicated in dementia; however, it is unclear whether epigenetic changes can be detected in peripheral tissue. This study aimed to systematically review the evidence for an association between dementia and peripheral DNA methylation. Forty-eight studies that measured DNA methylation in peripheral blood were identified, and 67% reported significant associations with dementia. However, most studies were underpowered and limited by their case-control design. We emphasize the need for future longitudinal studies on large well-characterized populations, measuring epigenetic patterns in asymptomatic individuals. A biomarker detectable in the preclinical stages of the disease would have the greatest utility in future intervention and treatment trials.

KW - Alzheimer's disease

KW - Biomarker

KW - Blood

KW - Dementia

KW - DNA methylation

KW - Epigenetics

KW - Peripheral

UR - http://www.scopus.com/inward/record.url?scp=85035022150&partnerID=8YFLogxK

U2 - 10.1016/j.jalz.2017.10.002

DO - 10.1016/j.jalz.2017.10.002

M3 - Article

VL - 14

SP - 81

EP - 103

JO - Alzheimer's and Dementia

JF - Alzheimer's and Dementia

SN - 1552-5260

IS - 1

ER -